GlassScriptPhysician profile
Taylor Binkley
NPI 1447980842
$1,508.02
in general payments reported to CMS, 2019-2025
16 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $78.18 · 2023: $376 · 2024: $750 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,347 · Consulting Fee: $68.10 · Education: $15.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.64 |
| Consulting Fee | $68.10 |
| Education | $15.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $267.70 | 2022-2025 | Fasenra, Saphnelo |
| Tg Therapeutics, INC. | $221.70 | 2023-2024 | |
| Janssen Biotech, INC. | $211.83 | 2022-2025 | Tremfya, Stelara |
| Lundbeck LLC | $132.85 | 2023 | Vyepti |
| Lilly USA, LLC | $125.95 | 2024 | Omvoh |
| Amgen INC. | $125.00 | 2025 | Uplizna |
| Horizon Therapeutics Plc | $107.72 | 2023 | Tepezza, Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $74.63 | 2024-2025 | Hyqvia, Cuvitru, Entyvio |
| Adma Biomanufacturing LLC | $68.10 | 2024-2025 | |
| Invivyd INC | $49.71 | 2025 | Pemgarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.70 | 2022 | |
| Tersera Therapeutics LLC | $23.48 | 2025 | Quzyttir |
| Organon LLC | $23.23 | 2023 | Renflexis |
| Eisai INC. | $19.58 | 2024 | |
| Abbvie INC. | $16.34 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.50 | 2023 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Binkley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.